Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer

Cancer

Volumn 116, Issue 1, 2010, Pages 137-145

  Wang, Xin Shelley ^a   Shi, Qiuling ^a   Lu, Charles ^a   Basch, Ethan M ^b   Johnson, Valen E ^a   Mendoza, Tito R ^a   Mobley, Gary M ^a   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Nonsmall cell lung cancer; Patient reported outcome; Performance status; Survival analysis; Symptom; The M. D. Anderson Symptom Inventory

Indexed keywords

GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM;

ADULT; ADVANCED CANCER; AGED; APPETITE DISORDER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; CLINICAL FEATURE; CONSTIPATION; COUGHING; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTRESS SYNDROME; DROWSINESS; DYSPNEA; FATIGUE; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEMORY DISORDER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PARESTHESIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SLEEP DISORDER; SURVIVAL RATE; TREATMENT PLANNING; VALIDATION PROCESS; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DYSPNEA; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PAIN; PROGNOSIS; PROSPECTIVE STUDIES; SLEEP DISORDERS;

EID: 74549186434     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24703     Document Type: Article

References (30)

1. Cooley ME. Symptoms in adults with lung cancer. A systematic research review. J Pain Symptom Manage. 2000;19:137-153.
2. Temel JS, Pirl WF, Lynch TJ. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2006;7:241-249.
3. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;37:16-21.
4. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
5. Gralla RJ, Griesinger F. Interpreting clinical trials in lung cancer: impact of methodology and endpoints. J Thorac Oncol. 2007;2:S51-S58.
6. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536-1543.
7. Tishelman C, Petersson LM, Degner LF, Sprangers MAG. Symptom prevalence, intensity, and distress in patients with inoperable lung cancer in relation to time of death. J Clin Oncol. 2007;25:5381-5389.
8. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer. 1991;67:3131-3135.
9. Gralla RJ, Thatcher N. Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer. 2004;46: S41-S47.
10. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of 4 tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16:3662-3673.
11. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage. 1995;10:423-431.
12. Efficace F, Bottomley A, Smit EF, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17:1698-1704.
13. Belani CP, Pereira JR, von Pawel J, et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer. 2006;53:231-239.
14. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355-1363.
15. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer. 2000;89:1634-1646.
16. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
17. Given B, Given CW, Sikorskii A, et al. Establishing mild, moderate, and severe scores for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points? J Pain Symptom Manage. 2008;35:126-135.
18. Benedetti C, Brock C, Cleeland C, et al. NCCN practice guidelines for cancer pain. Oncology (Williston Park). 2000;14:135-150.
19. Mock V, Atkinson A, Barsevick A, et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park). 2000;14:151-161.
20. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
22. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
23. Simon GR, Begum M, Bepler G. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol. 2008;4:51-59.
24. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:902-906.
25. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007;356:2538-2540.
26. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277-284.
27. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
28. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82:1904-1908.
29. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479-487.
30. Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am. 2003;9:207-236.